Neurogene appoints Christina Shafer as Chief Commercial Officer, adds CFO to Board

Filed April 20, 2026 · Period ending April 20, 2026 · ~1 min read

Key Changes

• medium

  Christina Shafer appointed Chief Commercial Officer, a new executive role signaling potential preparation for product commercialization or scaling of commercial operations.

  Item 8.01 press release view on EDGAR →
• low

  Board expanded from six to seven directors; President & CFO Christine Mikail appointed as Class II director through 2028 annual meeting.

  Item 5.02 verify on EDGAR →
• low

  Mikail brings 20+ years biotech/pharma experience across strategy, business development, operations, and finance; has been with Neurogene since 2019.

  Item 5.02 verify on EDGAR →